Bactroban is a drug owned by Glaxosmithkline. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 20, 2014. Details of Bactroban's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6025389 | Pharmaceutical and veterinary compositions of mupirocin and methods for their preparation |
Oct, 2014
(10 years ago) |
Expired
|
| US5569672 | Compounds |
Oct, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Bactroban is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Bactroban's family patents as well as insights into ongoing legal events on those patents.
Bactroban's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Bactroban's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 20, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bactroban Generic API suppliers:
Mupirocin Calcium is the generic name for the brand Bactroban. 5 different companies have already filed for the generic of Bactroban, with Fougera Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Bactroban's generic
About Bactroban
Bactroban is a drug owned by Glaxosmithkline. It is used for treating nasal passage infections and secondary infections of skin lesions caused by Methicillin-resistant S. aureus and S. pyogenes. Bactroban uses Mupirocin Calcium as an active ingredient. Bactroban was launched by Glaxosmithkline in 1997.
Approval Date:
Bactroban was approved by FDA for market use on 11 December, 1997.
Active Ingredient:
Bactroban uses Mupirocin Calcium as the active ingredient. Check out other Drugs and Companies using Mupirocin Calcium ingredient
Treatment:
Bactroban is used for treating nasal passage infections and secondary infections of skin lesions caused by Methicillin-resistant S. aureus and S. pyogenes.
Dosage:
Bactroban is available in the following dosage forms - ointment form for nasal use, cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM | Discontinued | TOPICAL |
| EQ 2% BASE | OINTMENT | Discontinued | NASAL |